Article

Top refractive surgery pearl: Pay attention to the tear film

Refractive surgeons need to remember that the tear film is the most important refracting surface of the eye, and if it is abandoned, surgical outcomes will suffer, said Eric D. Donnenfeld, MD, clinical professor of ophthalmology, New York University.

Refractive surgeons need to remember that the tear film is themost important refracting surface of the eye, and if it isabandoned, surgical outcomes will suffer, said Eric D.Donnenfeld, MD, clinical professor of ophthalmology, New YorkUniversity.

"We all know that dry eye is very common after LASIK and PRK,"Dr. Donnenfeld said. "A recent review of the world literatureshowed about one-third of patients have dry eye before LASIK andthe same proportion have dry eye after LASIK. Paying attention todry eye will yield dividends in terms of providing patients withbetter visual acuity and quality of vision."

Surgeons should consider the multiple treatment options availableto improve the condition of the ocular surface. Significantadvances have been made in artificial tear technology, and theseproducts continue to play an important role. Dr. Donnenfeld,however, also advocated more aggressive strategies, includingimmunomodulation with a topical cyclosporine ophthalmic emulsion(Restasis, Allergan).

"There are now several good studies to show that topicalimmunomodulation with cyclosporine both improves dry eye andprevents progression of the disease as well as studies to showthat when used preoperatively, topical cyclosporine dramaticallyimproves the ocular surface and outcomes after LASIK," hesaid.

Dr. Donnenfeld also said that he strongly believes inrecommending nutritional supplements, and that, in his opinion,punctal occlusion is not used often enough. In addition, surgeonsshould remember that treating the ocular surface encompassesaddressing eyelid disease in addition to the tear film. Patientsshould be evaluated for blepharitis/meibomianitis and treatedappropriately with hyperthermia and pharmacologic therapy, hesaid.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.